September quarter revenue rises 50%, standalone profit jumps to Rs 31 crore

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionExceptional ItemNegative Operating CashflowResults View source PDF Explain this filing

INDSWFTLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+10.3%Reaction day

₹377.15

prior close

₹380.45

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%+9.6% vs market

Pharmaceuticals peers, median of 171sector+0.4%+10.0% vs sector

On the reaction day the stock moved 9.6 pts more than Nifty Microcap 250 and 10.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+7.1

10m

+4.5

15m

+7.5

30m

+9.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+10.3+0.7+9.6+0.4+10.0

Next day

-1.9pendingpending-0.6-1.3

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Standalone revenue for the September 2026 quarter rose 50.2% to Rs 234.89 crore from Rs 156.43 crore, while net profit jumped 254% to Rs 31.03 crore from Rs 8.76 crore. Consolidated net profit rose 328% to Rs 34.22 crore. EBITDA increased to Rs 42.33 crore from Rs 8.55 crore. Half-year standalone profit was Rs 55.47 crore, but operating cash flow was negative Rs 33.49 crore. Auditor reviews were unqualified. Exceptional items were Rs 57.97 lakh.

Likely market impact

Strong revenue and profit growth may support the stock, but negative operating cash flow and exceptional items may limit investor confidence.